ONCOLYTICS BIOTECH WKN: A2JMW5 ISIN: CA6823108759 Kürzel: ONYN Forum: Aktien Thema: Hauptdiskussion

https://markets.businessinsider.com/analysts-opinions/oncolytics-biotech-inc-registered-shs-buy-752324

Weltklasse

Ziehhhh

Ich bin mit ner Posi drinw

Keiner mehr hier???

👀

Ist es eine solide Aktie?

http://crweworld.com/article/news-provided-by-pr-newswire/1465419/oncolytics-biotech-announces-favourable-aware-1-safety-update

Bist Du rein, Schorsch?

Danke, Schorsch11!

Catalysts bis 2021 AWARE-1 breast cancer study: interim data Roche / Tecentriq® Q4 2019 Complete enrollment in AWARE-1 breast cancer study Roche / Tecentriq® Q1 2020 Initiate phase 2 study BRACELET-1 study in HR+ / HER2- mBC Pfizer & Merck KGaA / Bavencio® Q1 2020 Confirm multiple myeloma phase 2 protocol with FDA Merck / Keytruda® 1H 2020 AWARE-1 breast cancer study: final data Roche / Tecentriq® Q2 2020 Phase 2 second *** pancreatic cancer study: interim data (ASCO)* Merck / Keytruda® Q2 2020 Complete enrollment in phase 2 second *** pancreatic cancer study* Merck / Keytruda® Mid-2020 Phase 2 second *** pancreatic cancer study: final data* Merck / Keytruda® 2H 2020 Complete enrollment in BRACELET-1 metastatic breast cancer study Pfizer & Merck KGaA / Bavencio® Q4 2020 Phase 1 multiple myeloma study: interim data (ASH)* Bristol-Myers Squibb / Opdivo® Q4 2020 Phase 2 multiple myeloma study: interim data (ASH)* Merck / Keytruda® Q4 2020 Phase 2 BRACELET-1 metastatic breast cancer study: interim data Pfizer & Merck KGaA / Bavencio® Q4 2020 Phase 2 BRACELET-1 metastatic breast cancer study: final data Pfizer & Merck KGaA / Bavencio® 1H 2021

488 gelistete Patente https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-K529LG-85640 20 klinische Studien https://clinicaltrials.gov/ct2/results?cond=&term=Oncolytics+Biotech+&cntry=&state=&city=&dist=

MARKET CAP 97,260,002 SHARES 25,010,089 AV. DAILY VOLUME 1,590,955

Cash: 12.3mio$ Burn: 1.5mio$/month reicht noch für 4 bis 5 Monate (Mai/Juni)

Catalysts: Pelareorep and Opdivo Multiple myeloma Phase 1 interim data due at ASH 2020. Pelareorep and Tecentriq - AWARE-1 Breast cancer Phase 1b interim data due end of 2019 (moved to 1Q 2020 due to no update). with final data due 1H 2020. Pelareorep with Keytruda Pancreatic cancer Phase 2 interim data due at ASCO 2020. Pelareorep with Keytruda Multiple myeloma Phase 2 trial to be initiated 2H 2019 with interim data due at ASH 2020. Pelareorep, paclitaxel and avelumab - BRACELET-1 HR+ / HER2- breast cancer Phase 2 trial planned for 1Q 2020 with interim data due 4Q 2020.

WL